GREAT MINDS
THINK DIFFERENTLY

With a collective wealth of industry success, knowledge and drive, our leaders share a passion for reinvigorating healthcare.

SCOTT TARRIFF

Founder, Chief
Executive Officer, Director

  • Scott Tarriff Founder, Chief Executive Officer, Director

    Scott leads Eagle with more than 25 years of industry experience. Scott founded Eagle in 2007 with the objective of utilizing the 505(b)(2) pathway to maximize the potential of proven medicines. Prior to founding the company, Scott held several key executive-level positions at publicly traded companies, including Bristol-Myers Squibb and Par Pharmaceutical. Scott quickly rose through the ranks at Bristol-Myers Squibb prior to joining Par. While at Par, he served as President and Chief Executive Officer from 2003 to 2006 and served on the board of directors from 2002 to 2006.

    Scott currently sits on the board of directors of Synthetic Biologics, Inc., Ziopharm Oncology, Inc., Hackensack Meridian Health, and Hackensack University Medical Center. He previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from 2009 to 2011, during its acquisition by Forest Laboratories, Inc.

    In 2016, Scott was awarded the prestigious Ernst and Young Entrepreneur Of The Year® Award in the Specialty Pharmaceutical category, New Jersey. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in areas such as innovation, financial performance, and personal commitment to their businesses and communities.

    Scott holds a BS in marketing from Pennsylvania State University and an MBA from Rider College.

DAVID PERNOCK

President and Chief
Commercial Officer

  • David Pernock President and Chief Commercial Officer

    David has been our President and Chief Commercial Officer since January 2017. David brings a wealth of pharmaceutical and biotechnology experience to the Eagle leadership team, having previously served as a member of the board from April 2015 through December 2016. David’s strategic focus and entrepreneurial spirit has contributed to the commercial success of many products throughout his distinguished career.

    Before joining Eagle, David served as Chairman of the board of directors and CEO (2010-2017) of Fibrocell Science, Inc., a publicly traded autologous cell and gene therapy company.

    David previously held various positions at GlaxoSmithKline, most notably serving as Senior Vice President of the Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care, and HIV Divisions. He also served as President of Reliant Pharmaceuticals and as a director of Martek Biosciences Corporation.

    David holds a BS in business administration from Arizona State University.

PETE A. MEYERS

Chief Financial Officer,
Principal Financial Officer,
Principal Accounting Officer

  • Pete A. Meyers Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer

    Pete joined Eagle in May 2017 with more than 2 decades of experience in the healthcare industry. From 2016 to 2017, he served as Chief Financial Officer of Motif BioSciences, Inc. Prior to joining Motif, Pete spent 3 years as Chief Financial Officer and Treasurer of TetraLogic Pharmaceuticals Corporation.

    Pete has 18 years of experience as a healthcare investment banker, including Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Pete currently serves on the board of directors and chairs the Audit Committee of Immutep Ltd.

    Pete holds a BS in finance from Boston College and an MBA in finance from Columbia Business School.

MICHAEL W. CORDERA

Executive Vice President,
General Counsel,
Chief Compliance Officer

  • Michael W. Cordera Executive Vice President, General Counsel, Chief Compliance Officer

    Mike joined Eagle in April 2016 as Deputy General Counsel and was promoted to General Counsel and Chief Compliance Officer in March 2018. Prior to joining Eagle, he held various legal positions with increasing responsibility at Warner Chilcott plc (2010–2014) and inVentiv Health (2014–2016).

    From 2001 until 2009, Mike was an associate at Shearman & Sterling LLP, where he focused on litigation and finance.

    Mike earned a BA in international affairs from The American University of Paris and his JD from Rutgers School of Law—Newark.

ADRIAN HEPNER, MD, PhD

Executive Vice President and
Chief Medical Officer

  • Adrian Hepner, MD, PhD Executive Vice President and Chief Medical Officer

    Adrian has over 25 years of experience in US and international clinical research and drug development. He has been our Chief Medical Officer since January 2015. His experience includes the development and implementation of the clinical and regulatory strategies for a multiple number of products from early-stage development through successful New Drug Application (NDA) and EU regulatory filings.

    Prior to Eagle, Adrian’s roles included Vice President of Clinical Research at Avanir Pharmaceuticals, Vice President of Clinical Research and Medical Affairs at BioDelivery Sciences International (BDSI), and Senior Medical Director at UCB BioSciences, Inc. Additionally, he spent 17 years in neuropsychiatry, private practice.

    Adrian has published more than 20 papers and has been issued several patents for his work.

    Adrian received his MD and PhD from the University of Buenos Aires. He spent a number of years as a post-doctoral fellow in Neuro-Psychopharmacology at the University of Ottawa. Additionally, Adrian completed visiting research physician experiences in the Department of Psychiatry at Harvard Medical School and the Department of Neurology at the National Institute of Mental Health.

DANIEL O’CONNOR

Executive Vice President,
Biologics and Corporate
Development

  • Daniel O’Connor Executive Vice President, Biologics and Corporate Development

    Dan is our Executive Vice President of Biologics and Corporate Development. Dan served as Finance Director from 2011 to May 2013, and has held multiple roles at Eagle during his tenure.

    Prior to joining Eagle in 2007, Dan held a variety of management positions, such as Senior Analyst at Ethicon (a Johnson & Johnson Company subsidiary) and Lead Finance Liaison throughout Ethicon’s joint venture with Omrix Biopharmaceuticals. Dan additionally held several finance positions at Ranbaxy Pharmaceuticals Inc. (a wholly owned subsidiary of Ranbaxy Inc.), which markets generic products in the US.

    Dan holds a BS in business administration from West Virginia University and an MBA from Rutgers University.

CHARLES WESCOTT

Senior Vice President,
Research and Development

  • Charles Wescott Senior Vice President of Research and Development

    Charles has over 20 years of drug discovery and development experience in the biotechnology and pharmaceutical industries. He has served in leadership roles guiding various stages of the drug development process, ranging from early-phase compound discovery through formulation, to preclinical development. His research efforts have led to the advancement of small-molecule, peptide, protein, and antibody drugs with indications in a variety of therapeutic areas including oncology, inflammation, cystic fibrosis, and diagnostic imaging.

    At Eagle, Charles leads the development of next-generation formulations of small molecules and biologics that address important patient and caregiver needs by overcoming significant drug delivery challenges.

    Charles is the author of over 20 scientific publications and an inventor of numerous patents in the field of drug discovery and development.

    Charles received his PhD in chemistry from the Massachusetts Institute of Technology.

BOARD OF
DIRECTORS

MICHAEL GRAVES

Chairman, Executive Committee Chair,
Compensation Committee Chair, Audit Committee

  • Michael Graves Chairman, Executive Committee Chair, Compensation Committee Chair, Audit Committee

    Mike has served as a member of Eagle’s board of directors since 2013. Mike is Chairman of the board of directors of Nanocopoeia, Inc., and a member of the board of directors of RiboCor, Inc. Mike has a wide variety of pharmaceutical industry experience including his position as CEO and President of Paddock Laboratories, Inc., and multiple leadership positions leading to President of the Generic Products Division at Par Pharmaceutical from 1998 – 2006.

SCOTT TARRIFF

Chief Executive Officer, Board
Member, Executive Committee

  • Scott Tarriff BOD Chief Executive Officer, Board Member, Executive Committee

    Scott leads Eagle with more than 25 years of industry experience. Scott founded Eagle in 2007 with the objective of utilizing the 505(b)(2) pathway to maximize the potential of proven medicines. Prior to founding the company, Scott held several key executive-level positions at publicly traded companies, including Bristol-Myers Squibb and Par Pharmaceutical. Scott quickly rose through the ranks at Bristol-Myers Squibb prior to joining Par. While at Par, he served as President and Chief Executive Officer from 2003 to 2006 and served on the board of directors from 2002 to 2006.

    Scott currently sits on the board of directors of Synthetic Biologics, Inc., Ziopharm Oncology, Inc., Hackensack Meridian Health, and Hackensack University Medical Center. He previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from 2009 to 2011, during its acquisition by Forest Laboratories, Inc.

DOUGLAS L. BRAUNSTEIN, J.D.

Board Member, Compensation Committee

  • Douglas L. Braunstein, J.D. Board Member, Compensation Committee

    Doug has over 30 years of industry experience and is currently the managing partner and founder of Hudson Executive Capital LP. During his career at JPMorgan Chase & Co., Doug served as CFO, Vice Chairman, and Head of America’s Investment Banking and Global M&A departments. Doug also served on several committees, including the Operating Committee, Executive Committee, and Investment Bank Management Committee.

    Doug is a trustee of Cornell University and a member of Cornell’s Investment Committee for the Endowment and Co-Chair of the Finance Committee. He also serves on Harvard Law School’s Dean’s Advisory Board. Doug is a member of the Economic Club of New York, a Board Member of the Foreign Policy Association, a member of the UJA of Greater New York’s Wall Street and Financial Services Division, and is on the Board of Directors of the Gordon A. Rich Memorial Foundation.

RICHARD A. EDLIN, J.D.

Board Member, Nominating and Corporate
Governance Committee

  • Richard A. Edlin, J.D. Board Member, Nominating and Corporate Governance Committee

    Rich is currently the Vice Chair, Chair of Litigation Practice in New York and the Business & Regulatory Financial Services Litigation Group, and a member of the Executive Committee of the law firm Greenberg Traurig, LLP.

    Rich is a member of the Board of Trustees of the Urban Justice Center; a member of the Board of Directors for Judges and Lawyers Breast Cancer Alert (JALBCA); a member of the Board of Governors of Hackensack University Medical Center; a trustee of The Carnegie Council for Ethics in International Affairs; a member of the Board of Governors, American Friends of Tel Aviv University; a member of the Economic Club of New York; a fellow of the Litigation Council of America; and a trustee of New Jersey SEEDS, among other professional and community activities.

SANDER FLAUM

Board Member, Nominating and Corporate Governance
Committee Chair, Compensation Committee

  • Sander Flaum Board Member, Nominating and Corporate Governance Committee Chair, Compensation Committee

    Sander has served as a principal of Flaum Navigators, a healthcare consultancy firm that he founded in January 2005. Since August 2004, he has also served as CEO of Flaum Partners, Inc., another healthcare consultancy firm that he founded. From 1991 to 2002, Sander served as CEO of Robert A. Becker EURO/RSCG, a predecessor to Euro RSCG Life.

    Prior to that, he held various positions during an 18-year career at Lederle Laboratories. As a member of the Euro RSCG Healthcare Global Network, he has served as its Co-Chairman since 1998. He also serves on the board of directors of Ohio State University’s Fisher College of Business and College of Arts and Science, The James Cancer Center at the OSU Medical Center, and The Fordham Gabelli Graduate School of Business. Additionally, Sander is Chair of the Fordham Leadership Forum at the Fordham Gabelli Graduate School of Business, where he serves as an Adjunct Professor. He is also Vice Chairman of the American Institute for Stuttering and Edge4Vets.

ROBERT L. GLENNING

Board Member, Nominating and Corporate Governance Committee, Audit Committee

  • Robert L. Glenning Board Member, Nominating and Corporate Governance Committee, Audit Committee

    Bob has over 30 years of experience in the healthcare industry and currently serves as President of the Financial Services Division and CFO at Hackensack Meridian Health, the most comprehensive healthcare delivery network in the state of New Jersey. He previously served as Executive Vice President and CFO of Hackensack University Health Network. From 2002 to 2007, Bob served as EVP and CFO of Kaleida Health, Inc. Prior to Kaleida Health, he served as VP and CEO of Acute Care at Northeast Health and Albany Memorial Hospital. Robert began his career at PricewaterhouseCoopers.

    Bob holds leadership positions on various boards including President of Univera Community Health and Treasurer for Visiting Nursing Association of WNY & VNA Home Care Services. Bob also serves as a member of the Healthcare Management Financial Association.

STEVEN RATOFF

Board Member, Audit Committee Chair

  • Steven Ratoff Board Member, Audit Committee Chair

    Steve has served as a member of our board of directors since Eagle’s inception in 2007. From 2010, he has served as President and Chief Executive Officer of NovaDel Pharma, Inc., filling a number of executive positions since joining their board of directors in 2005, and is currently serving as its Chairman. Prior to NovaDel, Steve held various executive positions with Cima Labs, Inc., MacroMed, Inc., and Brown-Forman Corporation. In 2004, Steve began his ongoing tenure as a venture partner of ProQuest Investments.